In the treatment of moderately to severely active RA

SIMPONI® dosing offers the fewest injections of all SC anti-TNF options1-4

  SIMPONI®
autoinjector + MTX1
Humira®
(adalimumab)
pen2
Cimzia®
(certolizumab pegol)
prefilled syringe3
Enbrel®
(etanercept)
autoinjector4
Minimum number of injections first year

SIMPONI® autoinjector + MTX Minimum number of injections first year

Humira® Minimum number of injections first year

Cimzia® Minimum number of injections first year

Enbrel® Minimum number of injections first year

Dosing schedule for adults with RA 50 mg once a month

40 mg every other week

Some patients with RA not receiving MTX may benefit from increasing the frequency to 40 mg every week.

Loading dose:
400 mg at Weeks 0, 2, and 4

Maintenance dose:
200 mg every other week (400 mg every 4 weeks can be considered)

50 mg once a week
Dosage form and strength 50 mg per 0.5 mL of solution 40 mg per 0.8 mL of solution 200 mg per 1 mL of solution 50 mg per 0.98 mL of solution
Indications

SIMPONI® is indicated for the treatment of adults with moderately to severely active RA, in combination with MTX.

 

Humira® is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. Humira® can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). Cimzia® is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis Enbrel® is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. Enbrel® can be initiated in combination with methotrexate or used alone.

See below for additional dosing information.

Minimum number of injections first year

SIMPONI® autoinjector + MTX1 SIMPONI® autoinjector + MTX Minimum number of injections first year 12
Humira® (adalimumab) pen2 Humira® Minimum number of injections first year 26
Cimzia® (certolizumab pegol) prefilled syringe3 Cimzia® Minimum number of injections first year 28
Enbrel® (etanercept) autoinjector4 Enbrel® Minimum number of injections first year 52

Dosing schedule for adults with RA

SIMPONI® autoinjector + MTX1

50 mg once a month

Humira® (adalimumab) pen2

40 mg every other week

Some patients with RA not receiving MTX may benefit from increasing the frequency to 40 mg every week.

Cimzia® (certolizumab pegol) prefilled syringe3

Loading dose: 400 mg at Weeks 0, 2, 4

Maintenance dose: 200 mg every other week (400 mg every 4 weeks can be considered)

Enbrel® (etanercept) autoinjector4

50 mg once a week

Dosage form and strength

SIMPONI® autoinjector + MTX1

50 mg per 0.5 mL of solution

Humira® (adalimumab) pen2

40 mg per 0.8 mL of solution

Cimzia® (certolizumab pegol) prefilled syringe3

200 mg per 1 mL of solution

Enbrel® (etanercept) autoinjector4

50 mg per 0.98 mL of solution

Indications

SIMPONI® autoinjector + MTX1

SIMPONI® is indicated for the treatment of adults with moderately to severely active RA, in combination with MTX.

Humira® (adalimumab) pen2

Humira® is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. Humira® can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).

Cimzia® (certolizumab pegol) prefilled syringe3

Cimzia® is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis

Enbrel® (etanercept) autoinjector4

Enbrel® is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. Enbrel® can be initiated in combination with methotrexate or used alone.

SIMPONI® is intended for use under the guidance and supervision of a physician. Patients may self-inject with SIMPONI® after physician approval and proper training.

Prior to initiating SIMPONI® and periodically during therapy, patients should be evaluated for active tuberculosis and tested for latent infection. Prior to initiating SIMPONI®, patients should be tested for hepatitis B viral infection.

This presentation is not intended to compare the safety, efficacy, or indications of these treatments. While these factors are important, there are additional considerations for selecting a treatment. Please refer to each product’s Prescribing Information for additional information, including recommended dosing and administration.

Humira® is a registered trademark of AbbVie Inc. Cimzia® is a registered trademark of UCB, Inc. Enbrel® is a registered trademark of Immunex Corporation.

References: 1. SIMPONI® (golimumab) Prescribing Information. Janssen Biotech, Inc. 2. Humira® (adalimumab) Prescribing Information. AbbVie Inc. 3. Cimzia® (certolizumab pegol) Prescribing Information. UCB, Inc. 4. Enbrel® (etanercept) Prescribing Information. Immunex Corporation.